Zlotta AR - Search Results

1

The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma.

Ordon M, Boerner S, Zlotta AR, Jewett MA, Fleshner N. Ordon M, et al. Among authors: zlotta ar. BJU Int. 2009 Dec;104(11):1641-5. doi: 10.1111/j.1464-410X.2009.08650.x. Epub 2009 Jul 2. BJU Int. 2009. PMID: 19583723

2

Prostate cancer prevention: past, present, and future.

Fleshner N, Zlotta AR. Fleshner N, et al. Among authors: zlotta ar. Cancer. 2007 Nov 1;110(9):1889-99. doi: 10.1002/cncr.23009. Cancer. 2007. PMID: 17893870 Free article. Review.

3

Pharmacotherapy for prostate cancer: the role of hormonal treatment.

Shahani R, Fleshner NE, Zlotta AR. Shahani R, et al. Among authors: zlotta ar. Discov Med. 2007 Aug;7(39):118-24. Discov Med. 2007. PMID: 18093474 Free article.

4

Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.

Al-Ghamdi AM, Lockwood G, Toi A, Kulkarni GS, Evans A, Finelli A, Zlotta AR, Fleshner N. Al-Ghamdi AM, et al. Among authors: zlotta ar. J Urol. 2008 Apr;179(4):1332-4. doi: 10.1016/j.juro.2007.11.067. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289588

5

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Musquera M, Fleshner NE, Finelli A, Zlotta AR. Musquera M, et al. Among authors: zlotta ar. Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073. Expert Rev Anticancer Ther. 2008. PMID: 18588452 Clinical Trial.

6

Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology.

Van der Kwast TH, Zlotta AR, Fleshner N, Jewett M, Lopez-Beltran A, Montironi R. Van der Kwast TH, et al. Among authors: zlotta ar. Anal Quant Cytol Histol. 2008 Dec;30(6):309-15. Anal Quant Cytol Histol. 2008. PMID: 19160695

7

'Prostatic evasive anterior tumours': the role of magnetic resonance imaging.

Lawrentschuk N, Haider MA, Daljeet N, Evans A, Toi A, Finelli A, Trachtenberg J, Zlotta A, Fleshner N. Lawrentschuk N, et al. BJU Int. 2010 May;105(9):1231-6. doi: 10.1111/j.1464-410X.2009.08938.x. Epub 2009 Oct 8. BJU Int. 2010. PMID: 19817743

8

Impact of positive surgical margins after radical prostatectomy differs by disease risk group.

Alkhateeb S, Alibhai S, Fleshner N, Finelli A, Jewett M, Zlotta A, Nesbitt M, Lockwood G, Trachtenberg J. Alkhateeb S, et al. J Urol. 2010 Jan;183(1):145-50. doi: 10.1016/j.juro.2009.08.132. J Urol. 2010. PMID: 19913824

9

Pathological stage review is indicated in primary pT1 bladder cancer.

van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, Bangma CH, Jewett MA, Zlotta AR. van Rhijn BW, et al. Among authors: zlotta ar. BJU Int. 2010 Jul;106(2):206-11. doi: 10.1111/j.1464-410X.2009.09100.x. Epub 2009 Dec 9. BJU Int. 2010. PMID: 20002439

10

The management of BCG failure in non-muscle-invasive bladder cancer: an update.

Zlotta AR, Fleshner NE, Jewett MA. Zlotta AR, et al. Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S199-205. doi: 10.5489/cuaj.1196. Can Urol Assoc J. 2009. PMID: 20019985 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters